Literature DB >> 2651134

The competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 attenuates the rate-decreasing effects of NMDA in rhesus monkeys without producing ketamine-like discriminative stimulus effects.

C P France1, J H Woods, P Ornstein.   

Abstract

The purported competitive excitatory amino acid antagonist CGS 19755 was compared to the non-competitive antagonists ketamine and MK-801 in three rhesus monkeys discriminating between 1.78 mg/kg of ketamine and saline while responding under a fixed-ratio 100 schedule of food presentation. MK-801 substituted completely for the ketamine discriminative stimulus and was 32 times more potent than ketamine as a discriminative stimulus. CGS 19755 was studied using single and cumulative dosing procedures up to a dose of 10.0 mg/kg; for all conditions, CGS 19755 produced responding exclusively on the saline lever and had only modest rate-decreasing effects. N-Methyl-D-aspartate administered alone also did not produce ketamine-appropriate responding but did decrease response rates in a dose-related manner. N-Methyl-D-aspartate eliminated responding in all monkeys at doses of 5.6-10.0 mg/kg. MK-801 and ketamine antagonized the rate-decreasing effects of N-methyl-D-aspartate, however, ketamine was most effective as an antagonist at doses that decreased response rates when administered alone. CGS 19755 also attenuated the rate-decreasing effects of N-methyl-D-aspartate and shifted the N-methyl-D-aspartate dose-effect curve more than 5-fold to the right. The magnitude of antagonism of N-methyl-D-aspartate appeared to be somewhat greater with CGS 19755 than with MK-801 or ketamine. Thus, a competitive (CGS 19755) and some non-competitive (MK-801 and ketamine) excitatory amino acid antagonists can attenuate the rate-decreasing effects of N-methyl-D-aspartate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2651134     DOI: 10.1016/0014-2999(89)90697-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Discriminative stimulus effects of NMDA, AMPA, and mGluR5 glutamate receptor ligands in methamphetamine-trained rats.

Authors:  Thomas E Wooters; Linda P Dwoskin; Michael T Bardo
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

Review 2.  A review of the in vitro and in vivo neurochemical characterization of the NMDA/PCP/glycine/ion channel receptor macrocomplex.

Authors:  P L Wood; T S Rao; S Iyengar; T Lanthorn; J Monahan; A Cordi; E Sun; M Vazquez; N Gray; P Contreras
Journal:  Neurochem Res       Date:  1990-02       Impact factor: 3.996

3.  Behavioural and electoencephalographic interactions between haloperidol and PCP/sigma ligands in the rat.

Authors:  S Sagratella; A Scotti de Carolis; A Pèzzola; P Popoli
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Competitive and uncompetitive N-methyl-D-aspartate antagonist discriminations in pigeons: CGS 19755 and phencyclidine.

Authors:  S P Baron; J H Woods
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

5.  Effects of competitive and non-competitive N-methyl-D-aspartate (NMDA) antagonists in squirrel monkeys trained to discriminate D-CPPene (SDZ EAA 494) from vehicle.

Authors:  J L Wiley; R L Balster
Journal:  Psychopharmacology (Berl)       Date:  1994-11       Impact factor: 4.530

6.  The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents.

Authors:  M Schmutz; C Portet; A Jeker; K Klebs; A Vassout; H Allgeier; R Heckendorn; G E Fagg; H R Olpe; H van Riezen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

7.  CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity.

Authors:  G E Fagg; H R Olpe; M F Pozza; J Baud; M Steinmann; M Schmutz; C Portet; P Baumann; K Thedinga; H Bittiger
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

8.  Drug discrimination based on the competitive N-methyl-D-aspartate antagonist, NPC 12626.

Authors:  J Willetts; D J Bobelis; R L Balster
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 9.  Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man.

Authors:  J McCulloch
Journal:  Br J Clin Pharmacol       Date:  1992-08       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.